Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olodaterol is a long-acting beta2-adrenergic receptor agonist (LABA) used as a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It works by selectively binding to and activating beta2-adrenoceptors in the lungs, leading to increased intracellular cAMP, activation of protein kinase A, and subsequent relaxation of airway smooth muscle. This results in bronchodilation and improved airflow for patients with COPD. Olodaterol is administered via oral inhalation once daily using a special inhaler device[1][2][5][8]. It is not indicated for acute exacerbations or asthma monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olodaterol.